Characteristics of second primary malignancies following bispecific antibodies therapy
Background The risk of secondary primary malignancies (SPMs) associated with bispecific antibody (BsAb)—a promising alternative to chimeric antigen receptor (CAR)-T therapy—remains insufficiently explored.Methods Using large-scale, real-world data from the US Food and Drug Administration’s Adverse E...
Saved in:
| Main Authors: | Dan Liu, Tong Li, Liang Wang, Jia Guo, Xinyu Zhou, Hongsheng Zhou, Xiaojie Liang, Baiwei Luo, Bingyu Lin, WeiXiang Lu, Shengyu Tian, Zihong Cai, Zhihao Jin, Keren Chen |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-04-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/13/4/e011200.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparison of CAR T-cell and bispecific antibody as third-line or later-line treatments for multiple myeloma: a meta-analysis
by: Dan Liu, et al.
Published: (2024-11-01) -
Correspondence on ‘Characteristics of second primary malignancies following bispecific antibodies therapy’ by Liang et al
by: Yan Jin, et al.
Published: (2025-05-01) -
The state of the art of bispecific antibodies for treating human malignancies
by: Shuhang Wang, et al.
Published: (2021-08-01) -
Bispecific antibody for lung cancer: mechanisms and clinical insights
by: Wei Chen, et al.
Published: (2025-05-01) -
Correction: Bispecific antibody for lung cancer: mechanisms and clinical insights
by: Wei Chen, et al.
Published: (2025-07-01)